Solanesol Modified Pluronic F127 Triblock Copolymeric Micelles for Anticancer Drug Delivery

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmaceutical Sciences

Background:

• Pluronic F127 micelles face limitations in stability and drug loading for pharmaceutical applications.
• Carrier materials with inherent bioactivity can offer synergistic therapeutic effects and reduce toxicity.
• Solanesol (SOL), a natural polyisoprenoid, possesses antitumor properties and good lipophilicity.

Purpose of the Study:

• To synthesize and characterize a novel pH-sensitive nanocarrier by conjugating a solanesol derivative (monosolanesyl succinate, MSS) to Pluronic F127.
• To evaluate the drug loading capacity, stability, and in vitro/in vivo antitumor efficacy of the developed nanocarrier loaded with doxorubicin (DOX).
• To explore the potential of F127-MSS-DOX micelles as a synergistic cancer therapeutic system.

Main Methods:

• Synthesis of monosolanesyl succinate (MSS) and its conjugation to Pluronic F127 via an amide bond.
• Preparation and characterization of doxorubicin-loaded F127-MSS micelles (F127-MSS-DOX), including particle size, drug loading capacity, and critical micelle concentration (CMC).
• In vitro cytotoxicity assays on cancer cell lines (HepG-2, MCF-7) and in vivo antitumor studies in tumor-bearing models.

Main Results:

• F127-MSS exhibited a 10-fold lower CMC than F127, indicating enhanced micelle stability.
• F127-MSS-DOX micelles achieved a drug loading capacity of ~6.2%, four times higher than F127-DOX micelles, with an average particle size of ~130 nm.
• The nanocarrier demonstrated pH-responsive drug release, improved stability, inherent antitumor effects from MSS, and significant in vivo tumor inhibition with reduced systemic toxicity compared to free DOX.

Conclusions:

• The F127-MSS nanocarrier significantly improves stability and drug loading capacity compared to unmodified Pluronic F127.
• The pH-sensitive F127-MSS-DOX micelles offer effective tumor-targeted drug delivery and exhibit synergistic antitumor effects.
• This novel nanocarrier system holds great promise for enhancing cancer therapy by combining improved drug delivery with intrinsic pharmacological activity.